guidanc increas post-jan dalla
news rais ep guidanc high end
market close rais adjust ep guidanc
midpoint vs current street estim
estim present competitor confer
tomorrow expect hear key driver
guidanc rais separ news along cardin
su oklahoma attorney gener relat on-going opioid
investig remind three compani discuss focu final
global settlement relat current opioid litig
matter ep rais show busi momentum
mckesson guidanc rais follow close quarter highlight current
busi momentum well stabil recent volatil market driver
support market data steadi gener price brand increas in-lin
expect compani decemb sell-side day focu cadenc
growth remaind achiev high end previou guidanc
new rang show piec busi good bad
deliv strong total result would expect share react favor
guidanc increas posit distributor sentiment broadli
compon led increas rang particular balanc oper
vs capit deployment-driven import magnitud perform also peer
indic present today
earli januari brand inflat mid-singl digit in-lin expect
support view end market stabl follow today news increas
ep estim captur current momentum increas ep
ep driven combin higher
oper estim higher gm core us pharma distribut busi
lower opex well increment capit deploy contribut increas
po back higher estim repres
price-to-earnings support impli valuat mck stake
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
largest drug distributor us
well sizabl busi canada europ
includ distribut retail pharmaci asset
largest medical-surg distributor
non-acut care market offer variou
suppli chain servic technolog although
recent divest clinic health platform
compani base san francisco ca
buy rate driven long-
term cash flow gener stori trade
overli punit market discount think
steadi revenu gener provid
low- mid-single-digit core ebit growth
compani even headwind around
pricing/volum also view
core compet around continu
deploy strong cash flow gener toward
supplement growth addit share
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
price object base roughli ep estim multipl
five year averag five year high also
repres bigger averag discount vs last year discount
incorpor modest growth slowdown seen within well rest
pharma suppli chain group
downsid risk po increment wors drug price pressur increas
competit creat gross profit headwind risk amazon anoth disrupt
forc enter suppli chain market on-going uncertainti headlin relat
opioid litig process lack avail attract capit deploy
opportun upsid risk potenti volum pickup increas buyside/sellsid
spread opportun cost save capit deploy contribut
michael cherni herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
